All News Top News Sep 4, 2019 Teva to Present New Analyses of Fremanezumab Efficacy and Safety in Adult Patients with Difficult-to-Treat Migraine at 19th Congress of the International Headache Society Learn More Share Top News Sep 3, 2019 Teva Announces United States Department of Commerce Appointment of Brendan O’Grady to Investment Advisory Council Learn More Share Top News Sep 3, 2019 Teva to Present New Analyses of Fremanezumab Efficacy and Safety in Adult Patients with Difficult-to-Treat Migraine at 19th Congress of the International Headache Society Learn More Share Top News Aug 21, 2019 Fremanezumab Data in The Lancet Demonstrate Clinically Meaningful Reduction in Monthly Migraine Days Versus Placebo for Patients with Difficult-To-Treat Migraine Learn More Share Top News Aug 20, 2019 Teva Announces Availability of a Generic Equivalent of EpiPen Jr® (epinephrine injection, USP) Auto-Injector, 0.15 mg in the United States Learn More Share
Top News Sep 4, 2019 Teva to Present New Analyses of Fremanezumab Efficacy and Safety in Adult Patients with Difficult-to-Treat Migraine at 19th Congress of the International Headache Society Learn More
Top News Sep 3, 2019 Teva Announces United States Department of Commerce Appointment of Brendan O’Grady to Investment Advisory Council Learn More
Top News Sep 3, 2019 Teva to Present New Analyses of Fremanezumab Efficacy and Safety in Adult Patients with Difficult-to-Treat Migraine at 19th Congress of the International Headache Society Learn More
Top News Aug 21, 2019 Fremanezumab Data in The Lancet Demonstrate Clinically Meaningful Reduction in Monthly Migraine Days Versus Placebo for Patients with Difficult-To-Treat Migraine Learn More
Top News Aug 20, 2019 Teva Announces Availability of a Generic Equivalent of EpiPen Jr® (epinephrine injection, USP) Auto-Injector, 0.15 mg in the United States Learn More